Ankara Training and Research Hospital, University of Health Sciences, Hacettepe Mh. Ulucanlar Cd. No: 89, 06230, Altındağ, Ankara, Turkey.
Int Ophthalmol. 2024 Mar 29;44(1):164. doi: 10.1007/s10792-024-03094-w.
To compare anti-vascular endothelial growth factor (anti-VEGF) treatment in pachychoroid neovasculopathy (PNV) and age related macular degeneration (AMD).
Cases having pro re nata (PRN) anti-VEGF treatment for choroidal neovascularization were reviewed and grouped as PNV and AMD. Groups were compared according to central foveal thickness (CFT), best corrected visual acuity (BCVA), and total injection over 12 months. The correlation of beginning choroidal thickness, CFT, and BCVA with final BCVA was analyzed.
Forty-seven PNV and 65 AMD cases were reviewed. Both the PNV group (p = 0.0001) and the AMD group (p = 0.003) had a significant improvement in BCVA and a significant decrease in CFT (p = 0.0001). However, BCVA was better at the 3-, 6-, and 12-month follow-up in PNV (p = 0.003, 0.002, 0.02). No significant CFT difference was observed between groups. The total number of injections was 5.7 ± 1.7 for PNV and 5.2 ± 1.5 for AMD (p = 0.09). Beginning BCVA was positively correlated with final BCVA in both groups.
The PRN treatment regimen was effective for PNV and AMD in terms of visual and anatomical outcomes. Visual response was better in PNV with PRN treatment with the same number of injections.
比较脉络膜新生血管（pachychoroid neovasculopathy，PNV）和年龄相关性黄斑变性（age related macular degeneration，AMD）中抗血管内皮生长因子（anti-VEGF）治疗的效果。
回顾了接受抗 VEGF 按需治疗脉络膜新生血管的病例，并根据病变类型分为 PNV 和 AMD 两组。比较两组的中心凹视网膜厚度（central foveal thickness，CFT）、最佳矫正视力（best corrected visual acuity，BCVA）和 12 个月内的总注射次数。分析开始时脉络膜厚度、CFT 和 BCVA 与最终 BCVA 的相关性。
共回顾了 47 例 PNV 和 65 例 AMD 病例。PNV 组（p=0.0001）和 AMD 组（p=0.003）的 BCVA 均有显著改善，CFT 均显著降低（p=0.0001）。然而，PNV 组在 3、6 和 12 个月的随访中 BCVA 更好（p=0.003、0.002、0.02）。两组间 CFT 无显著差异。PNV 组的总注射次数为 5.7±1.7，AMD 组为 5.2±1.5（p=0.09）。两组的开始 BCVA 均与最终 BCVA 呈正相关。
在视觉和解剖学结果方面，PNV 和 AMD 的 PRN 治疗方案均有效。在相同注射次数的 PRN 治疗下，PNV 的视觉反应更好。
Zotero 插件